BlossomHill Therapeutics (NASDAQ:BLSM) Stock Rating Upgraded by Guggenheim

Key Points

• Guggenheim upgraded BlossomHill Therapeutics to “strong buy,” adding to broadly positive analyst coverage. The stock has a consensus “strong buy” rating and an average price target of $32.20.
• Recent analyst targets range from $28 to $36, while BLSM opened at $18.99 and has traded between $15.25 and $20.61 over the past year.
• Insiders made significant purchases last quarter, acquiring 1.57 million shares worth approximately $25.2 million, including director Bihua Chen’s $5 million purchase.

BlossomHill Therapeutics (NASDAQ:BLSM - Get Free Report) was upgraded by equities research analysts at Guggenheim to a "strong-buy" rating in a report released on Tuesday, Zacks reports.

A number of other analysts have also recently commented on BLSM. Leerink Partners assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an "outperform" rating and a $36.00 target price on the stock. Lifesci Capital initiated coverage on BlossomHill Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $32.00 price target on the stock. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research report on Tuesday. They set an "overweight" rating and a $28.00 price target on the stock. Wall Street Zen upgraded BlossomHill Therapeutics to a "hold" rating in a research note on Saturday, August 15th. Finally, HC Wainwright started coverage on BlossomHill Therapeutics in a report on Tuesday. They issued a "buy" rating and a $35.00 price objective for the company. Three investment analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. Based on data from MarketBeat.com, BlossomHill Therapeutics has a consensus rating of "Strong Buy" and an average target price of $32.20.

BlossomHill Therapeutics Price Performance

BLSM opened at $18.99 on Tuesday. BlossomHill Therapeutics has a one year low of $15.25 and a one year high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In other BlossomHill Therapeutics news, Director Bihua Chen acquired 312,500 shares of the business's stock in a transaction on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, for a total transaction of $5,000,000.00. Following the completion of the transaction, the director owned 3,614,034 shares of the company's stock, valued at $57,824,544. The trade was a 9.47% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John P. Schmid bought 6,000 shares of BlossomHill Therapeutics stock in a transaction on Monday, August 10th. The stock was acquired at an average cost of $16.00 per share, with a total value of $96,000.00. Following the acquisition, the director owned 6,000 shares of the company's stock, valued at $96,000. This trade represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last quarter, insiders bought 1,573,900 shares of company stock worth $25,181,900.

BlossomHill Therapeutics Company Profile

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company's lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source